In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD).
What’s most transformative about this drug approval is that this is the first time the FDA – the governmental arbiter of safe and effective medicine in the United States – has approved any substance derived from the cannabis sativa plant and validated certain therapeutic benefits of cannabidiol. The FDA is, to some extent, endorsing what has been anecdotally accepted by the masses for millennia.
